Proposed multiple sclerosis topics
- Is bone marrow transplantation the ultimate treatment in aggressive disease?
- Cognitive dysfunction is improved by MS specific DMD
- In patients with clinical evidence of MS-like disease and a confirmatory MRI, CSF examination can be avoided in most cases
- Progressive forms of MS respond to agents used for relapsing forms of the disease
- MS is primarily an inflammatory disease with secondary neurodegeneration
- Should treatment be stopped in patients with apparently inactive diseases for 5 years?
- Second line therapies should be first line in patients with aggressive disease
- Is the switch from ethical to generic drugs safe and justified?
- Are MS therapies safe and effective in the elderly?
- Is the central vein syndrome really helpful in differentiating MS from other white-matter disease
- Should we consider immune reconstitution for patients with more active MS?
List of invited speakers
|
Joao Jose Araujo Cerqeuira, Spain
Georgina Arrambide, Spain Joab Chapman, Israel Cris Constaninescu, UK Adam Czaplinski, Switzerland Mark Freedman, Canada Hans Peter Hartung, Germany Alicja Kalinowska, Poland Jera Kruja, Albania Jens Kuhle, Switzerland Ralf Linker, Germany David Leppert, Switzerland |
Jacek Losy, Poland
Ron Milo, Israel Xavier Montalban, Spain Friedemann Paul, Germany Uros Rot, Slovenia Krzystof Selmaj, Poland Olaf Stuve, USA Patrick Vermersch, France Brian Weinshenker, USA Bianca Weinstock-Guttman, USA Heinz Wiendl, Germany Robert Zivadinov, USA |
